Victor Banzon
Pulmonary Disease · Lewes, DENPI 1225073547
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $243,135 of the $300,285 with a category attached, or 81.0%. 36 manufacturers reported payments, led by AstraZeneca at 40.3% of the total. Reporting peaked in 2019 at $82,214 and has fallen 53.1% since, to $38,587 in 2025. Among pulmonary disease clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $561.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$121K
- Mallinckrodt Enterprises LLC$77K
- Mallinckrodt Hospital Products Inc.$63K
- Boehringer Ingelheim$25K
- Intuitive Surgical$5K
- Grifols USA, LLC$4K
- plus $5K from 30 others
Across 1 payment — averaging $6080.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$6K
What the payments were for
- Speaking & faculty fees$243,13581%
- Travel & lodging$38,47813%
- Food & beverage$15,9055%
- Education$2,7261%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 158 | $121,049 |
| Mallinckrodt Enterprises LLC | 61 | $77,151 |
| Mallinckrodt Hospital Products Inc. | 94 | $63,031 |
| Boehringer Ingelheim | 41 | $24,944 |
| Intuitive Surgical | 15 | $4,910 |
| Grifols USA, LLC | 17 | $3,941 |
| GSK | 40 | $1,155 |
| Genentech USA, Inc. | 12 | $667 |
| Jazz Pharmaceuticals Inc. | 5 | $448 |
| Sanofi | 14 | $420 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $297 |
| Bayer | 6 | $225 |
| Lilly USA, LLC | 5 | $201 |
| Harmony Biosciences LLC | 5 | $184 |
| Merck | 3 | $179 |
| Inari Medical, Inc. | 1 | $147 |
| ANI Pharmaceuticals, Inc. | 4 | $132 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Johnson & Johnson | 1 | $115 |
| AbbVie | 5 | $109 |
| Insmed, Inc. | 6 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Verona Pharma, Inc. | 5 | $86 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $84 |
| Sunovion Pharmaceuticals Inc. | 5 | $78 |
| Tactile Systems Technology Inc | 1 | $73 |
| Viatris Specialty LLC | 3 | $68 |
| Mylan Specialty L.p. | 3 | $63 |
| Novartis | 2 | $36 |
| Shire North American Group Inc | 2 | $34 |
| Philips North America LLC | 2 | $32 |
| United Therapeutics Corporation | 1 | $32 |
| Resmed Corp | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Electromed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$137,584
- BREZTRI$111,535
- OFEV$19,403
- Da Vinci Surgical System$4,713
- FASENRA$4,424
- Prolastin-C Liquid$3,693
- TEZSPIRE$2,472
- Esbriet$250
- DUPIXENT$250
- TRELEGY ELLIPTA$225
- SUNOSI$223
- AREXVY$204
- FLOWTRIEVER CATHETER, S$147
- CT THROMBECTOMY SYSTEM KIT$147
- XOLAIR$140
- WINREVAIR$125
- AIRSUPRA$125
- NUCALA$125
- JARDIANCE$125
- Adempas$122
How this compares
$300,285 in reported general payments places this provider in the 95th percentile of 39 pulmonary disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 404 | $399,812 |
| OfevNintedanib Esylate | 27 | $349,916 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 223 | $212,883 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 204 | $160,935 |
| Spiriva HandihalerTiotropium Bromide | 57 | $71,786 |
| Spiriva RespimatTiotropium Bromide | 53 | $65,747 |
| Incruse ElliptaUmeclidinium Bromide | 89 | $56,550 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $20,974 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $17,887 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $17,240 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 24 | $15,695 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 380 | $13,677 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 72 | $12,200 |
| Ventolin HfaAlbuterol Sulfate | 72 | $8,133 |
| Tiotropium Bromide | 12 | $6,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $1,155 | $634,537721 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $24,944 | $421,39492 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $121,049 | $246,466290 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 39 pulmonary disease providers in Delaware.
Other pulmonary disease in Lewes
- Vikas BatraLewes$17K
- Ercilia AriasLewes$11K
- Samih RaadLewes$9K
- Omar MahmoudLewes$2K
- Albert RizzoNewark$162K
- Michel SamahaMilford$94K
- Haroon RajaNewark$44K
- Ismael MatusNewark$27K
- David JawaharDover$9K
- Anthony VasileWilmington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.